Improvement in patients with comorbidity
Nucala reduces exacerbations in patients with co-morbid nasal polyps and asthma.1,2
In nasal polyps patients with comorbid asthma
SYNAPSE1,5
In patients with severe eosinophilic asthma with comorbid nasal polyps:
MENSA3/MUSCA4 - post hoc meta-analysis
SELECTED SAFETY INFORMATION
Warnings/Precautions: Should not be used to treat acute asthma exacerbations. Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after starting treatment. Abrupt discontinuation of corticosteroids after initiation of mepolizumab treatment is not recommended.
Allergic reactions: Acute and delayed systemic reactions, including hypersensitivity reactions, have occurred following administration of mepolizumab. Patients should be instructed to seek medical attention immediately if allergic reactions occur. In the event of a hypersensitivity reaction, appropriate treatment as clinically indicated should be initiated.
Parasitic infections: Pre-existing helminth infections should be treated before starting therapy. If patients become infected whilst receiving treatment with mepolizumab and do not respond to anti-helminth treatment, temporary discontinuation of therapy should be considered.
Organ-threatening or life-threatening manifestations of EGPA and HES: Has not been studied
Adverse reactions: In clinical studies in patients with severe refractory eosinophilic asthma and EGPA, headache, injection site reactions and back pain were the most commonly reported adverse reactions during treatment. In patients with CRSwNP: Headache and back pain. In patients with HES: Headache, urinary tract infection, injection site reactions and pyrexia.
Video guidance prefilled Pen
Video guidance prefilled Syringe
Video guidance Powder for solution
Need more information?
REFERENCES
- Han JK et al. Lancet Respir Med. 2021;9:1141-1153 (supplementary)
- Howarth P et al. J Allergy Clin Immunol 2020;145(6):1713-1715
- Ortega HG et al. N Engl J Med. 2014;371(13):1198-1207
- Chupp G et al. Lancet Respir Med. 2017;5:390-400
- Han JK et al. Lancet Respir Med. 2021;9:1141-1153
- Juniper EF et al. Respir Med. 2005;99(5):553-558
- Juniper EF et al. Respir Med. 2006;100:616-621
PM-NO-MPL-WCNT-230004 June 2023